Neurologic adverse effects in pts with MM treated with cilta-cel in CARTITUDE-2

Updates on Clinical Data of Cilta-Cel in CARTITUDE-2 Cohort A among Progressive MM patientsПодробнее

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel in patients with progressive MMПодробнее

An update on CARTITUDE-2: cilta-cel in patients with multiple myeloma in second lineПодробнее

CARTITUDE-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myelomaПодробнее

Characteristics of neurotoxicity associated with ide-cel in pts with RRMM in phase II KarMMaПодробнее

Latest Results from the CARTITUDE-2 Study Testing Cilta-cel in Multiple Myeloma PatientsПодробнее

Latest results from the CARTITUDE-2 trial of cilta-cel in progressive multiple myelomaПодробнее

Updated Results from CARTITUDE-1: Phase 1b/2Study of Cilta-Cel in Pts With RR Multiple MyelomaПодробнее

CARTITUDE-2: evaluating CAR T therapy Cilta-Cel in multiple myeloma patients who had early relapseПодробнее

Cilta-Cel Continues to Show Promise as a Treatment for Progressive Multiple MyelomaПодробнее

Initial results of cilta-cel, a CAR T-cell therapy, in earlier lines of treatmentПодробнее

Updated Data from CARTITUDE-1 and CARTITUDE-2 Studies Testing Cilta-Cel in R/R Multiple MyelomaПодробнее

Safety and Efficacy of Cilta Cel: CARTITUDE-2 Study | Jens Hillengass, MD, PhD | ASH 2023Подробнее

Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapseПодробнее

CAR-T cell therapy neurotoxic complications predicted by Simple blood testПодробнее

CARTITUDE-2 trial update and management of neurotoxicitiesПодробнее

Comparison of outcomes with cilta-cel in CARTITUDE-1 vs RW SOC for pts w/ triple-class exposed RRMMПодробнее

Meta-analysis of cilta-cel in patients with R/R multiple myelomaПодробнее

Cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myelomaПодробнее